Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
28.58
-1.03 (-3.48%)
At close: Feb 21, 2025, 4:00 PM
28.70
+0.12 (0.42%)
After-hours: Feb 21, 2025, 7:10 PM EST
Vera Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
1.81B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VERA News
- 9 days ago - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Top 3 Health Care Stocks That Could Blast Off This Quarter - Benzinga
- 6 weeks ago - Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewsWire
- 4 months ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 4 months ago - Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - Benzinga
- 4 months ago - Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewsWire